Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | METAP2 | P50579 | 2/20 | 0.51 |
| ▸ | METAP1 | P53582 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7869387 | 0.81 | KDM4E (0.53) | KDM4ELMNASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL20001343 | 0.80 | ALDH1A1 (0.51) | KDM4ELMNASMN1; SMN2METAP2METAP1 | |
| SCHEMBL5215459 | 0.79 | RAB9A (0.55) | KDM4ELMNASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL4386263 | 0.78 | KDM4E (0.72) | KDM4ELMNASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL4775529 | 0.78 | MAPT (0.44) | KDM4ELMNASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL30988061 | 0.77 | EGFR (0.39) | KDM4ELMNASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL8914359 | 0.77 | MAPT (0.49) | KDM4ELMNASMN1; SMN2RAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL27496748 | 0.76 | KDM4E (0.59) | KDM4ELMNASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL334878 | 0.76 | RAB9A (0.60) | KDM4ELMNASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL7237106 | 0.75 | MEN1 (0.50) | KDM4ELMNARAB9AMETAP2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 841 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023151188-A1 | GREEN SYNTHESIS METHOD OF ANTIVIRAL DRUG INTERMEDIATE | 上海皓元医药股份有限公司 | 2023-08-17 | — | — | WO | claimed |
| CN-114671798-B | Green synthesis method of antiviral drug intermediate | 上海皓元医药股份有限公司 | 2022-08-16 | — | — | CN | claimed |
| CN-114671798-A | Green synthesis method of antiviral drug intermediate | 上海皓元医药股份有限公司 | 2022-06-28 | — | — | CN | claimed |
| EP-3053944-B1 | METHOD FOR PRODUCING POLYALKYLENE GLYCOL DERIVATIVE HAVING AMINO GROUP AT END, POLYMERIZATION INITIATOR FOR USE IN THE SAME, AND ALCOHOL COMPOUND AS RAW MATERIAL FOR THE POLYMERIZATION INITIATOR | SHINETSU CHEMICAL CO (JP) | 2021-10-06 | — | — | EP | claimed |
| WO-2012145932-A1 | A NOVEL PROCESS FOR THE PREPARATION OF PERAMIVIR AND INTERMEDIATES THEREOF | PHARMARESOURCES (SHANGHAI) CO., LTD. (CN) | 2012-11-01 | — | — | WO | claimed |
| US-20120214994-A1 | (3-FLUORO-2-HYDROXY)PROPYL-FUNCTIONALIZED ARYL DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR THE DIAGNOSIS OR TREATMENT OF NEURODEGENERATIVE BRAIN DISEASES | FUTURECHEM CO., LTD. (KR) | 2012-08-23 | — | — | US | claimed |
| EP-1514542-B1 | Medicinal composition comprising Tacrine or Donepezil for improving brain function. | TOYAMA CHEMICAL CO LTD (JP) | 2012-02-22 | — | — | EP | claimed |
| US-6534658-B1 | Intermediates for producing pharmaceuticals | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-03-18 | — | — | US | claimed |
| US-5120746-A | Inhibit gastric acid secretion | TOYAMA CHEMICAL CO., LTD. (JP) | 1992-06-09 | — | — | US | claimed |
| US-4767863-A | Isoxazoline intermediates | BRISTOL-MYERS COMPANY (US) | 1988-08-30 | — | — | US | claimed |
| US-4643849-A | ANTIULCER, ANTISECRETORY AGENTS | TOYAMA CHEMICAL CO., LTD. (JP) | 1987-02-17 | — | — | US | claimed |
| US-4267340-A | BACTERICIDES; SYNTHESIS OF PENICILLINS AND CEPHALOSPORINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-05-12 | — | — | US | claimed |
| US-4246405-A | Method for preparation of β-lactam compound | FUJISAWA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1981-01-20 | — | — | US | claimed |
| US-4009159-A | PENICILLINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1977-02-22 | — | — | US | claimed |
| US-3993646-A | Process for the ring expansion of penicillins to cephalosporin compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1976-11-23 | — | — | US | claimed |
| US-3978063-A | 1,2,3,4-Tetrahydroisoquinoline derivatives and the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1976-08-31 | — | — | US | claimed |
| CN-118284608-A | Compounds as BCL-2 inhibitors | 重庆复创医药研究有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118215661-A | Compounds as BCL-2 inhibitors | 重庆复创医药研究有限公司 | 2024-06-18 | — | — | CN | disclosed |
| US-3963725-A | 1,2,3,4-Tetrahydroisoquinoline derivatives and the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1976-06-15 | — | — | US | disclosed |
| US-3954732-A | BACTERICIDAL PENICILLINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214994-A1 | (3-FLUORO-2-HYDROXY)PROPYL-FUNCTIONALIZED ARYL DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR THE DIAGNOSIS OR TREATMENT OF NEURODEGENERATIVE BRAIN DISEASES | APP, FABP7, SLC3A2 | KDM4E 3569/4885LMNA 2823/4885SMN1; SMN2 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.